Prospects for new restorative and neuroprotective treatments in Parkinson's disease

Nature

Volumn 399, Issue SUPPL., 1999, Pages

  Dunnett, Stephen B ^a   Björklund, Anders ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; CATECHOL METHYLTRANSFERASE; DNA FRAGMENT; LEVODOPA; METHAMPHETAMINE; SELEGILINE;

AUTOOXIDATION; BRAIN DEGENERATION; CELL DEATH; DIAGNOSTIC ACCURACY; DIZYGOTIC TWINS; EXON; GENE MAPPING; GENE TRANSFER; HUMAN; LEWY BODY; MONOZYGOTIC TWINS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0040368216     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/399a032     Document Type: Review

References (99)

1. Forno, L. S. in Parkinson's Disease (ed. Stern, G.) 185-238 (Chapman & Hall, London, 1990).
2. Goedert, M., Jakes, R. & Spillantini, M. G. α-Synuclein and the Lewy body. Neurosci. News 1, 47-52 (1998).
3. Olanow, C. W. & Tatton, WG. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144 (1999).
4. Perl, D. P., Olanow, C. W. & Calne, D. B. Alzheimer's disease and Parkinson's disease; distinct entities or extremes of a spectrum of neurodegeneration? Ann. Neurol. (suppl.) 44, S19-S31 (1998).
5. Gasser, T. Genetics of Parkinson's disease. Ann. Neurol. 44, S53-S57 (1998).
6. Tanner, C. M. et al. Parkinson's disease in twins: an etiologic study. J. Am. Med. Assoc. 281, 341-346 (1999).
7. Brooks, D. J. The early diagnosis of Parkinson's disease. Ann. Neurol. (suppl.) 44, S10-S18 (1998).
8. Langston, J. W. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann. Neurol. (suppl.) 44, S45-S52 (1998).
9. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-890 (1997).
10. Mezey, E. et al. α-Synuclein in neurodegenerative disorders: murderer or accomplice? Nature Med. 4, 755-757 (1998).
11. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early onset Parkinson's disease. Nature Med. 4, 1318-1320 (1998).
12. Poewe, W. & Granata, R. in Movement Disorders. Neurological Principles and Practice (eds Watts, R. L. & Koller, W. C.) 201-219 (McGraw-Hill, New York, 1997).
13. Marsden, C. D. & Parkes, J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1, 345-349 (1977).
14. Marsden, C. D., Linazasoro, G. & Obeso, J. A. An introduction to the new surgery for Parkinson's disease: past and present problems. Adv. Neurol. 74, 143-147 (1997).
15. DeLong, M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285 (1990).
16. Starr, P. A., Vitek, J. L. & Bakay, R. A. E. Ablative surgery and deep brain stimulation for Parkinson's disease. Neurosurgery 43, 989-1013 (1998).
17. Pollak, P., Benabid, A. L., Limousin, P. & Benazzouz, A. Chronic intracerebral stimulation in Parkinson's disease. Adv. Neurol. 74, 213-220 (1997).
18. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455 (1973).
19. Fearnley, J. & Lees, A. J. Parkinson's disease: neuropathology. Brain 114, 2283-2301 (1991).
20. McGeer, P. L., Itagaki, S., Akiyama, H. & McGeer, E. G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574-576 (1989).
21. Calne, D. B. & Langston, J. W. Aetiology of Parkinson's disease. Lancet 2, 1457-1459 (1983).
22. Olanow, C. W., Jenner, P. & Beal, M. F. Cell death and neuroprotection in Parkinson's disease. Ann. Neurol. (suppl.) 44, S1-S196 (1998).
23. Mizuno, Y. et al. in Movement Disorders. Neurological Principles and Practice (eds Watts, R. L. & Koller, W. C.) 161-182 (McGraw-Hill, New York, 1997).
24. Jenner, P. & Olanow, C. W. Understanding cell death in Parkinson's disease. Ann. Neurol. (suppl.) 44, S72-S84 (1998).
25. Ebadi, M., Srinivasan, S. K. & Baxi, M. D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48, 1-19 (1996).
26. Schapira, A. H. V., Cooper, J. M. & Dexter, D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269 (1989).
27. Burke, R. E. & Kholodilov, N. G. Programmed cell death: does it play a role in Parkinson's disease? Ann. Neurol. (suppl.) 44, S126-S133 (1998).
28. Tatton, N. A., Maclean-Fraser, A., Tatton, W. G., Perl, D. P. & Olanow, C. W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. (suppl.) 44, S142-S148 (1998).
29. Marsden, C. D. & Olanow, C. W. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann. Neurol. (suppl.) 44, S189-S196 (1998).
30. Shoulson, I. et al. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann. Neurol. 43, 318-325 (1998).
31. Koller, W. C. Neuroprotection for Parkinson's disease. Ann. Neurol. (suppl.) 44, S155-S159 (1998).
32. Olanow, C. W., Jenner, P. & Brooks, D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. (suppl.) 44, S167-S174 (1998).
33. Rodriguez, M. C., Obeso, J. & Olanow, C. W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. (suppl.) 44, S175-S188 (1998).
34. Hagg, T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149, 183-192 (1998).
35. Unsicker, K., Suter-Crazzolara, C. & Krieglstein, K. Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-β. Ciba Found. Symp. 196, 70-80 (1996).
36. Gash, D. M., Zhang, Z. M. & Gerhardt, G. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. (suppl.) 44, S121-S125 (1998).
37. Björklund, A., Rosenblad, C., Winkler, C. & Kirik, D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4, 186-200 (1997).
38. Palfi, S. et al. Clinical and pathological evaluation of patient with Parkinson's disease (PD) following intracerebroventricular (icv) GDNF. Soc. Neurosci. Abstr. 24, 41 (1998).
39. Snyder, S. H. et al. Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 19, 21-26 (1998).
40. Steiner, J. P., Hamilton, G. S., Ross, D. T. & Valentine, H. L. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl Acad. Sci. USA 94, 2019-2124 (1997).
41. Constantini, L. C. et al. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol. Dis. 5, 97-106 (1998).
42. Green, D. R. & Reed, J. C. Mitochondria and apoptosis. Science 281, 1309-1312 (1999).
43. Schierle, G. S. et al. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Med. 5, 97-100 (1999).
44. Dunnett, S. B. & Björklund, A. functional Neural Transplantation (Raven, New York, 1994).
45. Lindvall, O. Neural transplantation: a hope for patients with Parkinson's disease? NeuroReport 8, iii-x (1997).
46. Olanow, C. W., Freeman, T. B. & Kordower, J. H. Neural transplantation as a therapy for Parkinson's disease. Adv. Neurol. 74, 249-269 (1997).
47. Wenning, G. K. et al. Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107 (1997).
48. Kordower, J. H., Freeman, T. B. & Olanow, C. W. Neuropathotogy of fetal nigral grafts in patients with Parkinson's disease. Mov. Dis. 13, 88-95 (1998).
49. Kordower, J. H. et al. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 6, 213-219 (1997).
50. Boer, G. J. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J. Neurol. 242, 1-13 (1994).
51. Kordower, J. H., Goetz, C. G., Freeman, T. B. & Olanow, C. W. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp. Neurol. 144, 41-46 (1997).
52. Zawada, W. M. et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 786, 96-103 (1998).
53. Sinclair, S. R., Svendsen, C. N., Torres, E. M., Fawcett, J. W. & Dunnett, S. B. The effects of glial cell line-derived neurotrophic factor (GDNF) on embryonic nigral grafts. NeuroReport 7, 2547-2552 (1996).
54. Rosenblad, C., Martinez-Serrano, A. & Björklund, A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75, 979-985 (1996).
55. Yurek, D. M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 153, 195-202 (1998).
56. Pakzaban, P. & Isacson, O. Neural xenotransplantation: reconstruction of neuronal circuitry across species barriers. Neuroscience 62, 989-1001 (1994).
57. Isacson, O. & Breakefield, X. O. Benefits and risks of hosting animal cells in the human brain. Nature Med. 3, 964-969 (1997).
58. Deacon, T. et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Med. 3, 350-353 (1997).
59. Butler, D. Last chance to stop and think on risks of xenotransplants. Nature 391, 320-324 (1998).
60. Mayer, E., Dunnett, S. B. & Fawcett, J. W. Mitogenic effect of basic fibroblast growth factor on embryonic ventral mesencephalic dopaminergic neurone precursors. Dev. Brain. Res. 72, 253-258 (1993).
61. Bouvier, M. M. & Mytilineou, C. Basic fibroblast growth factor increases division and delays differentiation of dopamine precursors in vitro. J. Neurosci. 15, 7141-7149 (1995).
62. Studer, L., Tabar, V. & McKay, R. D. G. Transplantaton of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nature Neurosci. 1, 290-295 (1998).
63. Ling, Z. D., Potter, E. D., Lipton, J. W. & Carvey, P. M. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol. 149, 411-423 (1998).
64. Ye, W. L., Shimamura, K., Rubenstein, J. L. R., Hynes, M. A. & Rosenthal, A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93, 755-766 (1998).
65. Brundin, P., Duan, W.-M. & Sauer, H. in Functional Neural Transplantation (eds Dunnett, S. B. & Björklund, A.) 9-46 (Raven, New York, 1994).
66. Goetz, C. G. et al. United Parkinson Foundation neurotransplantation registry on adrenal medullary transplants: presurgical, and 1-year and 2-year follow up. Neurology 41, 1719-1722 (1991).
67. Winn, S. R., Wahlberg, L., Tresco, P. A. & Aebischer, P. An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp. Neurol. 105, 244-250 (1989).
68. Becker, J. B et al. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res. 508, 60-64 (1990).
69. Aebischer, P., Goddard, M., Signore, A. P. & Timpson, R. L. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Exp. Neurol. 126, 151-158 (1994).
70. Emerich, D. F. et al. Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats. Exp. Neurol. 122, 37-47 (1993).
71. Espejo, E. F., Montoro, R. J., Armengol, J. A. & López-Barneo, J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantaton of carotid body cell aggregates. Neuron 20, 197-206 (1998).
72. Fisher, L. J., Jinnah, H. A., Kale, L. C., Higgins, G. A. & Gage, F. H. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce 1-DOPA. Neuron 6, 371-380 (1991).
73. Lundberg, C., Horellou, P., Mallet, J. & Björklund, A. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxytase gene: in vitro characterisation and in vivo effects in the rat Parkinson model. Exp. Neurol. 139, 39-53 (1996).
74. Anton, R. et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp. Neurol. 127, 207-218 (1994).
75. Chase, T. N. et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39, 7-10 (1989).
76. Raymon, H. K., Thode, S. & Gage, F. H. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp. Neurol. 144, 82-91 (1997).
77. Kang, U. J. Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov. Dis. 13, 59-72 (1998).
78. Bencsics, C. et al. Double transduction with GTP cyclohydrolase L and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J. Neurosci. 16, 4449-4456 (1996).
79. Left, S. E., Rendahl, K. G., Spratt, S. K., Kang, U. J. & Mandel, R. J. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via compression of GTP cyclohydrolase 1 with tyrosine hydroxylase. Exp. Neurol. 151, 249-264 (1998).
80. Barker, R. A & Dunnett, S. B. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Exp. Brain Res. 101, 365-374 (1994).
81. Isacson, O. Behavioral effects and gene delivery in a rat model of Parkinson's disease. Science 269, 856-856 (1995).
82. Frim, D. M. et al. Implanted fibroblasts genetically engineered to produce brain derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl Acad. Sci. USA 91, 5104-5108 (1999).
83. Levivier, M., Przedborski, S., Bencsics, C. & Kang, U. J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15, 7810-7820 (1995).
84. Tseng, J. L., Baetge, E. E., Zurn, A. D. & Aebischer, P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17, 325-333 (1997).
85. Choi-Lundberg, D. L. et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841 (1997).
86. Mandel, R. J., Spratt, S. K., Snyder, R. O. & Leff, S. E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl Acad. Sci. USA 94, 14083-14088 (1997).
87. Bilang-Bleuel, A. et al. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 94, 8818-8823 (1997).
88. Choi-Lundberg, D. L. et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154, 261-275 (1998).
89. Blömer, U., Kafri, T., Randolph-Moore, L., Verma, I. M. & Gage, F. H. Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. Proc. Natl Acad. Sci. USA 95, 2603-2608 (1998).
90. Jordan, J. et al. Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth-factor. Mol. Pharmacol. 47, 1095-1100 (1995).
91. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119, 585-591 (1996).
92. Olanow, C. W. & Arendash, G. W. Metals and free radicals in neurodegeneration. Curr. Opin. Neurol. 7, 548-558 (1994).
93. Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
94. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
95. Leroy, M. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
96. Farrer, M. et al. Low frequency of α-synuclein mutations in familial Parkinson's disease. Ann. Neurol. 43, 394-397 (1998).
97. Gasser, T. et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet. 18, 262-265 (1998).
98. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18, 106-108 (1998).
99. Owen, A. M., Sahakian, B. J. & Robbins, T. W. in Memory in Neurodegenerative Disease: Biological, Cognitive and Clinical Perspectives (ed. Trosyter, A. I.) 157-171 (Cambridge Univ. Press, Cambridge, 1998).